Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models. |
|
Alterations in Gemin5 expression contribute to alternative mRNA splicing patterns and tumor cell motility |
|
Alterations in Pericyte Subpopulations Are Associated with Elevated Blood-Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer |
|
Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis |
|
The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models |
|
Basic and translational advances in cancer metastasis: Nm23. |
|
The biology of metastasis to a sanctuary site |
|
Brain Metastasis Cell Lines Panel: a public resource of organotropic cell lines |
|
A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity |
|
Breast cancer metastasis: issues for the personalization of its prevention and treatment |
|
Breast cancer metastasis to the central nervous system |
|
Cancer metastasis as a therapeutic target |
|
Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study |
|
Caveolin-1 upregulation mediates suppression of primary breast tumor growth and brain metastases by stat3 inhibition |
|
CNS metastases in breast cancer: old challenge, new frontiers |
|
Current issues in the management of breast cancer, c1999: |
|
DNA methyltransferase inhibitor, zebularine, delays tumor growth and induces apoptosis in a genetically engineered mouse model of breast cancer |
|
Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer |
|
Enhanced growth inhibition by combined DNA methylation/HDAC inhibitors in lung tumor cells with silenced CDKN2A. |
|
A framework for the development of effective anti-metastatic agents |
|
A HER2 Antibody Drug Conjugate Controls Growth of Breast Cancer Brain Metastases in Hematogenous Xenograft Models, with Heterogeneous Blood-Tumor Barrier Penetration Unlinked to a Passive Marker |
|
Histidine kinases and histidine phosphorylated proteins in mammalian cell biology, signal transduction and cancer |
|
Identification and validation of genes with expression patterns inverse to multiple metastasis suppressor genes in breast cancer cell lines |
|
In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide |
|
In vivo characterization of changing blood-tumor barrier permeability in a mouse model of breast cancer metastasis: a complementary magnetic resonance imaging approach. |
|
In vivo single scan detection of both iron-labeled cells and breast cancer metastases in the mouse brain using balanced steady-state free precession imaging at 1.5 T. |
|
Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain. |
|
Inhibition of signal transduction by the nm23 metastasis suppressor: possible mechanisms |
|
Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. |
|
Limited fibrosis accompanies triple-negative breast cancer metastasis in multiple model systems and is not a preventive target. |
|
Massively parallel sequencing reveals an accumulation of de novo mutations and an activating mutation of LPAR1 in a patient with metastatic neuroblastoma |
|
MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer |
|
Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer |
|
Metastasis Suppressor Genes: Basic Biology and Potential Clinical Use |
|
Metastasis Suppressors NME1 and NME2 Promote Dynamin 2 Oligomerization and Regulate Tumor Cell Endocytosis, Motility, and Metastasis |
|
The mitochondrially-localized nucleoside diphosphate kinase D (NME4) is a novel metastasis suppressor |
|
Molecular basis for the critical role of suppressor of cytokine signaling-1 in melanoma brain metastasis |
|
Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo |
|
Nm23-h1 binds to gelsolin and inactivates its actin-severing capacity to promote tumor cell motility and metastasis |
|
Nm23-H1 homologs suppress tumor cell motility and anchorage independent growth |
|
Nm23-H1 metastasis suppressor expression level influences the binding properties, stability, and function of the kinase suppressor of Ras1 (KSR1) Erk scaffold in breast carcinoma cells |
|
Nm23-H1 metastasis suppressor phosphorylation of kinase suppressor of Ras via a histidine protein kinase pathway |
|
Nm23-H1 suppresses tumor cell motility by down-regulating the lysophosphatidic acid receptor EDG2. |
|
Notch1 inhibition alters the CD44hi/CD24lo population and reduces the formation of brain metastases from breast cancer. |
|
An open letter to the FDA and other regulatory agencies: Preclinical drug development must consider the impact on metastasis |
|
Opposing effects of pigment epithelium-derived factor on breast cancer cell versus neuronal survival: implication for brain metastasis and metastasis-induced brain damage |
|
Paclitaxel-hyaluronic nanoconjugates prolong overall survival in a preclinical brain metastases of breast cancer model |
|
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies |
|
Protein-protein interactions: a mechanism regulating the anti-metastatic properties of Nm23-H1. |
|
Proteomic approaches to the diagnosis, treatment, and monitoring of cancer |
|
Proteomics of human breast ductal carcinoma in situ. |
|
Rab11a differentially modulates epidermal growth factor-induced proliferation and motility in immortal breast cells |
|
A rapid ultra HPLC-MS/MS method for the quantitation and pharmacokinetic analysis of 3-deazaneplanocin A in mice |
|
Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases |
|
Therapeutics for Brain Metastases, v3. |
|
TMIC-34. STUDY OF ROLE OF ASTROCYTIC S1P3 IN REGULATING BLOOD-BRAIN/TUMOR BARRIER PERMEABILITY |
|
TMIC-37. THE MICROENVIRONMENT OF A YOUNGER BRAIN IS MORE PERMISSIVE FOR BREAST CANCER BRAIN METASTASIS |
|
Toward a drug development path that targets metastatic progression in osteosarcoma. |
|
TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells |
|
Translational approaches using metastasis suppressor genes |
|
Translational research in brain metastasis is identifying molecular pathways that may lead to the development of new therapeutic strategies |
|
Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis |
|
Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer |
|
Vinorelbine Delivery and Efficacy in the MDA-MB-231BR Preclinical Model of Brain Metastases of Breast Cancer |
|
Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts |
|
Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks |
|